

Schizophrenia Drug Market & Pipeline Insight

<https://marketpublishers.com/r/S9C5E30C0BDEN.html>

Date: June 2014

Pages: 386

Price: US\$ 1,200.00 (Single User License)

ID: S9C5E30C0BDEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could possibly be affected by this disease. There have been rare cases of young children and adolescents also being affected. Overall, in most cases, the development of schizophrenia in earlier stages implies that the disease is very severe. Additionally, it has also been observed that schizophrenia is more severe in men than in women.

Though schizophrenia has been in the realm of research for over a century, the actual cause of the disorder still remains unknown. Pharmacological treatments have been in wide use for many years. However, there is hardly any evidence that these treatments have significantly improved outcomes for most people with schizophrenia. The pharmaceutical companies in this market are currently facing and are expected to continue to face stiff competition from many generic atypical antipsychotics. The major target of differentiating the products through improved treatment of negative or cognitive symptoms, partial responders, as well as improved tolerability, and demonstration of cost-effectiveness are essential have become the main focus of the pharma companies in this market.

The future years are likely to witness a shift in the way in which this disease is perceived. With schizophrenia being considered as a neuro developmental disorder with psychosis as a late stage of illness, it is likely that the current unsatisfactory outcomes could change. Such new ideas of looking into schizophrenia as a neuro developmental disorder, which is substantially different from the way it has been treated previously,

offers much potential for future prevention and cure over the next two decades.

“Schizophrenia Drug Market & Pipeline Insight” Report Highlights:

Schizophrenia Drug Market Overview

Marketed Drug Profiles & Patent Analysis

Clinical Trial Insight by Phase & Country

Drug in Clinical Development Phase: 143

Majority Therapies in Preclinical Phase: 65

Marketed Schizophrenia Drugs: 16

Suspended & Discontinued Drug Profiles: 163

Competitive Landscape

Contents

1. SCHIZOPHRENIA DRUG MARKET OVERVIEW

1.1 Market Overview

1.2 Clinical Insight

2. SCHIZOPHRENIA DRUGS CLINICAL PIPELINE BY PHASE & COUNTRY

2.1 Unknown Phase

2.2 Research

2.3 Preclinical

2.4 Clinical

2.5 Phase I

2.6 Phase I/II

2.7 Phase II

2.8 Phase II/III

2.9 Phase III

2.10 Preregistration

3. MARKETED SCHIZOPHRENIA DRUGS CLINICAL INSIGHT & PATENT ANALYSIS

4. SUSPENDED & DISCONTINUED SCHIZOPHRENIA DRUG PROFILE

4.1 No Development Reported

4.2 Discontinued

4.3 Suspended

5. COMPETITIVE LANDSCAPE

5.1 Abbott Laboratories

5.2 Addex Pharmaceuticals

5.3 Astellas Pharma

5.4 Daiippon Sumitomo Pharma

5.5 Eli Lilly

5.6 GlaxoSmithKline

5.7 Johnson & Johnson

5.8 Merck

5.9 Pfizer

5.10 Roche

5.11 Sanofi

Figure 1-1: Schizophrenia Drug Market (US\$ Billion), 2013-2020

Figure 1-2: Schizophrenia Treatment Process in Future

Figure 1-3: Schizophrenia Drug Clinical Pipeline by Phase (%), 2014

Figure 1-4: Schizophrenia Drug Clinical Pipeline by Phase (Number), 2014

Figure 1-5: No Development Reported in Schizophrenia Drug Clinical Pipeline by Phase (%), 2014

Figure 1-6: No Development Reported in Schizophrenia Drug Clinical Pipeline by Phase (Number), 2014

Figure 1-7: Discontinued Schizophrenia Drug Clinical Pipeline by Phase (%), 2014

Figure 1-8: Discontinued Schizophrenia Drug Clinical Pipeline by Phase (Number), 2014

Figure 1-9: Suspended Schizophrenia Drug Clinical Pipeline by Phase (%), 2014

Figure 1-10: Suspended Schizophrenia Drug Clinical Pipeline by Phase (Number), 2014

List Of Tables

LIST OF TABLES

Following Information For Each Drug Profile is Covered in More than 200 Tables in Report:

Drug Profile Overview

Active Indication

Phase of Development

Country for Clinical Trial

Owner / Originator/ Licensee/Collaborator

Administrative Route

Drug Class

COMPANIES MENTIONED

Abbott Laboratories, Addex Pharmaceuticals, Astellas Pharma, Dainippon Sumitomo Pharma, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck

I would like to order

Product name: Schizophrenia Drug Market & Pipeline Insight

Product link: <https://marketpublishers.com/r/S9C5E30C0BDEN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S9C5E30C0BDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970